Press release
Primary Biliary Cholangitis Treatment Market to Reach US$2.72 Billion by 2033, Growing at 7.8% CAGR | North America Holds Significant Position with Highest Market Share | DataM Intelligence
Primary Biliary Cholangitis Treatment Market
According to DataM Intelligence, the global primary biliary cholangitis (PBC) treatment market reached US$1.33 billion in 2024 and is expected to reach US$2.72 billion by 2033, growing at a CAGR of 7.8% during the forecast period of 2025-2033. This steady growth is propelled by increasing prevalence and diagnosis rates of PBC, the launch of novel second-line therapies, high unmet need for patients non-responsive to first-line treatment, growing awareness among hepatologists, and favorable reimbursement scenarios for specialty drugs in key markets.
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/primary-biliary-cholangitis-treatment-market?jd
Report Details:
• No. of Pages: 180
• Forecast Period: 2025-2033
• Market Size (2024): $1.33 Billion
• Market Size (2033): $2.72 Billion
• Compound Annual Growth Rate: 7.8%
• Regions Covered: Global
Global Recent Developments (Sept-Nov 2025):
✅ November 2025: CymaBay Therapeutics' Seladelpar received full FDA approval following confirmatory Phase 3 data, establishing it as a potent new Drug Type for PBC with demonstrated benefits in both biochemical response and pruritus (itching) reduction, directly competing with Obeticholic Acid.
✅ October 2025: Intercept Pharmaceuticals announced positive long-term data for its next-generation FXR agonist, showing improved liver fibrosis outcomes in PBC patients, aiming to recapture market leadership as its patent for Obeticholic Acid (Ocaliva) nears expiration.
✅ September 2025: Genfit's Elafibranor reported positive topline results from its pivotal Phase 3 ELATIVE trial, meeting primary endpoints for PBC patients with an inadequate response to Ursodeoxycholic Acid (UDCA), positioning it for a potential 2026 NDA submission.
Buy Now and Enjoy a 30% Year-End Discount: https://www.datamintelligence.com/buy-now-page?report=primary-biliary-cholangitis-treatment-market
Competitive Landscape
The market is transitioning from a near-monopoly to a competitive landscape with the entry of novel agents.
1. Intercept Pharmaceuticals, Inc. maintained significant market share with Obeticholic Acid (Ocaliva), the first approved second-line therapy, though facing upcoming generic competition and new rivals.
2. CymaBay Therapeutics, Inc. (potentially acquired by a larger pharma) emerged as a new leader with the approval and launch of Seladelpar, capturing share due to its efficacy and pruritus benefit.
3. Genfit S.A. positioned itself as a near-term competitor with Elafibranor, pending regulatory approval.
4. Generic manufacturers of Ursodeoxycholic Acid (UDCA) supplied the foundational first-line therapy for the vast majority of PBC patients, representing a large volume but lower-value segment.
5. Other biotechs (e.g., Alimentiv with tropifexor) were advancing mid-stage pipeline candidates, indicating future competition.
Speak to Our Analyst and Get Customization in the Report: https://www.datamintelligence.com/customize/primary-biliary-cholangitis-treatment-market?jd
Segmentation Analysis
By Drug Type
• Ursodeoxycholic Acid (UDCA) remains the universal first-line therapy and the volume leader, used in over 90% of diagnosed patients. However, its low cost means it contributes less to market revenue growth.
• Obeticholic Acid has been the revenue driver as the primary second-line option. The market is now being reshaped by the launch of Seladelpar (a PPARδ agonist) and the anticipated entry of Elafibranor (a dual PPARα/δ agonist), which offer alternative mechanisms and improved side-effect profiles, particularly for pruritus.
By Age Group
• The market is overwhelmingly focused on the Adults segment, particularly women over 40, as PBC is primarily a disease of middle-aged women.
• The Geriatrics segment is also significant, as PBC is a chronic, progressive disease that patients live with for decades, requiring long-term management into older age.
Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription?jd
Regional Analysis:
North America is expected to hold a significant position in the global primary biliary cholangitis treatment market with the highest market share. This dominance is driven by the highest diagnosis rates, premium pricing for novel specialty drugs, favorable reimbursement through private and public insurance (Medicare), strong presence of leading pharmaceutical companies, and a well-established network of specialist hepatologists who actively manage PBC.
Europe is the second-largest market, with growth fueled by increasing diagnosis, centralized healthcare systems facilitating specialist care, and the approval and market access of new therapies through agencies like the EMA.
Market Trends & Drivers
The PBC treatment market is undergoing a significant evolution from a one-size-fits-all approach (UDCA) to a personalized, multi-drug treatment paradigm. Key trends include the development of combination therapies using UDCA with different second-line agents; intense focus on developing drugs that improve quality of life by targeting debilitating symptoms like pruritus and fatigue; the search for biomarkers to predict treatment response and guide therapy selection; and increased screening efforts to diagnose patients earlier in the disease course. The high unmet need in UDCA non-responders, the entry of new drug classes with distinct profiles, and the chronic nature of the disease requiring lifelong treatment are the primary market drivers.
Related Reports:
1. Liver Disease Treatment Market - https://www.datamintelligence.com/research-report/liver-disease-treatment-market?jd
2. Orphan Drugs Market - https://www.datamintelligence.com/research-report/orphan-drugs-market?jd
3. North America Liver Disease Treatment Market - https://www.datamintelligence.com/research-report/north-america-liver-disease-treatment-market?jd
Contact Us:
Sai Kiran
DataM Intelligence 4market Research LLP
Phone: +1 877-441-4866
Email: Sai.k@datamintelligence.com
About DataM Intelligence
DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specialises in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter, LinkedIn and Facebook.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Primary Biliary Cholangitis Treatment Market to Reach US$2.72 Billion by 2033, Growing at 7.8% CAGR | North America Holds Significant Position with Highest Market Share | DataM Intelligence here
News-ID: 4302189 • Views: …
More Releases from DataM Intelligence 4 Market Research LLP
Colombia Food Supplement Market to Reach US$662.30 Million by 2032, Growing at 7 …
Leander, Texas and Tokyo, Japan - Dec 03, 2025
According to DataM Intelligence, the Colombia food supplement market reached US$358.55 million in 2023, rising to US$379.20 million in 2024 and is expected to reach US$662.30 million by 2032, growing at a CAGR of 7.4% from 2025 to 2032. This strong growth is propelled by rising health consciousness, increasing disposable income, growing preventive healthcare focus, expansion of modern retail and e-commerce,…
1,3-Propanediol (PDO) Market Growing at 9.6% CAGR, Driven by Bio-Based Chemical …
The Global 1,3-Propanediol (PDO) Market was valued at US$ 424.5 million in 2023 and is expected to reach around US$ 799.5 million by 2030, growing at a CAGR of approximately 9.6% during the forecast period 2024-2030. Market growth is primarily driven by the rising shift toward bio-based and sustainable chemicals, increasing adoption of polytrimethylene terephthalate (PTT) in textiles and carpets, and expanding use of PDO in cosmetics, personal care formulations,…
Smartphone Camera Lens Market is expected to reach US$ 9.7 billion by 2030, Asia …
Global Smartphone Camera Lens Market reached US$ 5.5 billion in 2022 and is expected to reach US$ 9.7 billion by 2030, growing with a CAGR of 9.2% during the forecast period 2024-2031.
Consumers often prioritize camera quality when purchasing smartphones. Manufacturers respond by improving camera systems, including the lenses, sensors and image processing capabilities. It drives smartphone sales as users seek devices that meet their photography needs. High-quality photography enthusiasts are…
Allergy Diagnostics Market to Reach US$ 11.63 Bn by 2030 at 10.4% CAGR | Key Pla …
The Global Allergy Diagnostics Market was valued at US$ 6.54 billion in 2024 and is expected to reach US$ 11.63 billion by 2030, growing at a CAGR of 10.4% during the forecast period 2025-2030. Market expansion is driven by the rising prevalence of allergic diseases, such as respiratory allergies, food allergies and drug hypersensitivities, along with increasing pollution levels, lifestyle changes and heightened patient awareness. Allergy diagnostics, including test kits,…
More Releases for PBC
Primary Biliary Cirrhosis (PBC) Market Emerging Trends and Growth Prospects 2034
Introduction
Primary Biliary Cirrhosis (PBC), now often referred to as Primary Biliary Cholangitis, is a chronic autoimmune liver disease that slowly destroys bile ducts, leading to bile buildup, liver scarring, and eventual cirrhosis. It predominantly affects middle-aged women and is often associated with fatigue, itching, and complications that can severely impair quality of life.
With rising autoimmune disease prevalence, improved screening, and a growing focus on rare liver disorders, the global market…
Primary Biliary Cholangitis (PBC) Market Trends, Challenges and Growth Forecast
Primary Biliary Cholangitis (PBC) is a chronic autoimmune liver disease that progressively destroys intrahepatic bile ducts, leading to cholestasis, fibrosis, cirrhosis, and eventually liver failure. The condition predominantly affects middle-aged women and is often associated with fatigue, pruritus, and elevated liver enzymes. Without effective management, PBC can result in severe complications, including portal hypertension, hepatocellular carcinoma (HCC), and the need for liver transplantation.
The PBC market has historically relied on ursodeoxycholic…
Plain Bearing Market Is Booming Worldwide |PBC Linear, Timken Company, THK
Advance Market Analytics published a new research publication on "Plain Bearing Market Insights, to 2030" with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Plain Bearing market was mainly driven by the increasing R&D spending across the world.
Get Free Exclusive PDF Sample Copy of…
Sustainable Tourism Market May Set New Growth Story |Wilderness Safaris, Kind Tr …
Latest published market study on Global Sustainable Tourism Market provides an overview of the current market dynamics in the Sustainable Tourism space, as well as what our survey respondents—all outsourcing decision-makers—predict the market will look like in 2027. The study breaks market by revenue and volume (wherever applicable) and price history to estimates size and trend analysis and identifying gaps and opportunities. Some of the players that are in coverage…
Primary Biliary Cholangitis (PBC) Treatment Market is Set to Experience Revoluti …
Primary biliary cholangitis is also referred as primary biliary cirrhosis, is an autoimmune disease of liver that manifest into progressive cholestasis and lead to end-stage liver disease. Primary biliary cholangitis characterized by destruction of bile duct which transport the bile acid. Primary biliary cholangitis is detected in the late stage of disease. Primary biliary cirrhosis majorly seen in women’s in fourth or sixth decades of life. Primary biliary cholangitis generally…
Primary Biliary Cholangitis (PBC) Treatment Market : Analysis And Forecast (2016 …
Primary biliary cholangitis, previously known as primary biliary cirrhosis, is a rare chronic liver disease, primarily characterized by destruction of the bile ducts which transport bile acid out of the liver. Although the primary cause of the disease has not yet been elucidated, research across the world has attributed it to be autoimmune in nature. The progress of this disease results in the harmful accumulation of bile acid, which causes…
